Application of ihMT MRI in Multiple Sclerosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorAssistance Publique Hopitaux De Marseille

About this trial

The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.

Eligibility criteria

Qualifiers

Adult patient, male and female, age 18 to 45

Patient affiliated with health insurance coverage,

Patient who signed a free and informed consent after receiving detailed, understandable and honest information,

Patient with relapsing-remitting multiple sclerosis according to the McDonald 2010 criteria

Disqualifiers

Patients with the usual contraindications for MRI (pacemaker, agitation, metal shards, claustrophobia)

Patients at risk of non-compliance to the exam: basic problems with understanding, confusion, involuntary movements, poor tolerance of prolonged supine position

Patients who are unable to give their consent: problems with understanding, lack of vigilance, confusion

Woman who is pregnant and breastfeeding

Trial design

Treatments tested in this trial

  • inhomogeneous Magnetisation Transfer (ihMT) sequence
  • inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T

Treatment groups

85 Participants
are divided into 4 treatment groups